Arrowhead's Gene-Silencing Drugs Show Promise in Early Obesity Studies, Enhancing Weight Loss When Combined with Zepbound
核心洞察
Arrowhead Pharmaceuticals reported that its gene-silencing candidate ARO-INHBE, when combined with Eli Lilly's Zepbound, helped obese patients with diabetes (搜索) lose 9.4% of their weight after 16 weeks compared to 4.8% with Zepbound alone.
The combination therapy demonstrated superior fat reduction, with patients losing 23% of visceral fat, 15% of total fat, and 77% of liver fat, significantly outperforming Zepbound monotherapy.
ARO-INHBE represents the first clinical demonstration that targeting the Activin E (搜索)/ALK7 (搜索) pathway can therapeutically improve body composition in obese patients with type 2 diabetes (搜索), a population that typically responds less well to incretin-based therapies.
Arrowhead Pharmaceuticals announced promising interim results from Phase 1/2 studies of its gene-silencing obesity (搜索) candidates, demonstrating enhanced weight loss when combined with existing treatments and marking the first clinical validation of a novel therapeutic pathway for metabolic disease (搜索).
Enhanced Weight Loss in Diabetes Patients
In an ongoing Phase 1/2 study, patients with obesity (搜索) and diabetes (搜索) who received two doses of ARO-INHBE spaced one month apart in combination with Eli Lilly's Zepbound achieved 9.4% weight loss after 16 weeks, nearly doubling the 4.8% weight loss seen with Zepbound alone. This patient population typically experiences reduced response to incretin-based therapies compared to those without diabetes.
The combination therapy demonstrated particularly striking results in fat reduction. Participants lost 23% of their visceral fat—the most harmful type stored around organs—compared to just 7% with Zepbound monotherapy. Total fat reduction reached 15% versus 5% for Zepbound alone, while liver fat decreased by an impressive 77% compared to 20% with the standalone treatment.
First-in-Human Validation of Novel Pathway
According to James Hamilton, M.D., MBA, Chief Medical Officer and Head of R&D at Arrowhead, these results represent "the first demonstration in humans that the Activin E (搜索)/ALK7 (搜索) pathway, a genetically validated pathway that regulates adipose fat storage, may potentially be harnessed therapeutically to improve body composition and enhance weight loss versus tirzepatide treatment alone."
ARO-INHBE is designed to reduce hepatic expression of the INHBE gene and its secreted product, Activin E (搜索). Loss-of-function INHBE variants in humans are associated with improved fat distribution and lower risk of metabolic diseases including type 2 diabetes (搜索). The drug works by inhibiting a pathway that regulates energy homeostasis in adipose tissue, potentially increasing lipolysis and reducing visceral adiposity and insulin resistance.
Monotherapy Results Show Promise
As a standalone treatment, ARO-INHBE demonstrated dose-dependent reductions in serum Activin E (搜索), achieving a mean maximum reduction of 85% after a single 400 mg dose, with maximum observed reduction reaching 94%. Single-dose monotherapy at week 16 led to 9.9% mean visceral fat reduction, 38% liver fat reduction, and a 3.6% increase in total lean tissue.
Two doses of ARO-INHBE monotherapy achieved 15.6% mean visceral fat reduction at week 24, adjusted for placebo, demonstrating sustained efficacy with repeated dosing.
Second Candidate Targets Adipose Tissue
Arrowhead's second obesity (搜索) candidate, ARO-ALK7, achieved the distinction of being "the first RNAi-therapeutic to show adipocyte gene target silencing in a clinical trial." The drug targets the ACVR1C (搜索) gene to reduce production of Activin receptor-like kinase 7 (ALK7 (搜索)), achieving dose-dependent reductions in adipose ALK7 mRNA with a mean reduction of 88% at the 200 mg dose at week 8.
A single dose of ARO-ALK7 led to rapid, dose-dependent reductions in mean visceral fat, with a 14.1% reduction observed at week 8, adjusted for placebo. In large genetic datasets, reduced ACVR1C (搜索) expression has been associated with healthier adipose distribution and reduced risk of obesity (搜索)-related metabolic complications.
Addressing Current Treatment Limitations
Hamilton noted that while incretin-based therapies have advanced obesity (搜索) treatment, "shortcomings around loss of lean mass, tolerability related to GI effects, reduced response in patients with diabetes (搜索), and disproportional fat mass gain after cessation of therapy remains a challenge for many patients."
The interim results suggest that targeting the Activin E (搜索)/ALK7 (搜索) pathway may address some limitations in current standard-of-care obesity (搜索) treatments, particularly for patients with diabetes (搜索) who typically experience less weight loss with incretin therapy and are less likely to reach weight loss targets.
Safety Profile
Both candidates have demonstrated generally good tolerability profiles. ARO-INHBE has been well tolerated as monotherapy and in combination with tirzepatide, with most treatment emergent adverse events being mild in severity. No adverse events led to study or drug discontinuation, and injection site reactions were generally mild and self-limited.
For ARO-ALK7, no clinically significant adverse laboratory trends were identified, including liver enzymes and glycemic parameters. Most adverse events were mild, with no discontinuations or serious adverse events reported.
The frequency of gastrointestinal adverse events was similar between combination therapy and tirzepatide monotherapy groups, suggesting the gene-silencing approach does not exacerbate the GI side effects commonly associated with incretin-based treatments.